Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Temozolomide Capsules in strengths of 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg. Temozolomide capsules is a chemotherapy drug used in the management of brain tumors.
The group also received the final approval from the USFDA to market Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg. Nadolol is used in management of hypertension (high blood pressure) and angina pectoris (chest pain).
Both the drugs will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
